Q-omics provides the consensus-scored GOLGA2P7 profile across patient tissues and cancer cell-line models. GOLGA2P7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GOLGA2P7 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, GOLGA2P7 RNA expression shows 18,060 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, COAD, and ACC as cancer lineages where GOLGA2P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA2P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA2P7 survival associations across molecular data types. GOLGA2P7 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA2P7 RNA expression–survival associations across cancer types. High GOLGA2P7 expression shows unfavorable associations in LIHC, KICH, KIRP and LUAD, but favorable associations in MESO and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GOLGA2P7 RNA expression.
This table summarizes GOLGA2P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA2P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA2P7 shows lower tumor expression in LUAD and higher tumor expression in COAD, KIRP, LIHC, UCEC and BLCA. The COAD box plot shows higher GOLGA2P7 RNA expression in tumor versus normal tissue (log2 FC = +0.478, t-test p < 0.001).
This table shows molecular features associated with GOLGA2P7 in patient tissues and cancer cell lines. In patient samples, GOLGA2P7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA2P7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
